43 results about "Heparan sulphate proteoglycan" patented technology

The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used. In a more preferred embodiment, the average molecular weight is about 40,000 to 500,000 Daltons. The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The invention further provides compositions and methods to inhibit glial cell invasion, detrimental bone growth and neurite outgrowth. In a preferred embodiment, the inhibitory compositions further comprise an adhesive protein.

The present invention relates to substantially pure mannan-binding lectin associated serine protease-2 (MASP-2) polypeptides and fragments thereof as well as nucleic acids encoding such polpeptides. Furthermore, the present invention relates to uses of a substantially pure polypeptide comprising amino acid sequences derived from mannan-binding lectin associated serine protease-2 (MASP2) or a functional homologue thereof for the production of a pharmaceutical composition as well as pharmaceutical compositions comprising MASP-2 and / or MASP-2 fragments. In addition the present invention relates to inhibitors of MASP-2 and pharmaceutical compositions comparing such inhibitors. Methods for detecting MASP-2 nucleic acid expression are included in the invention.

The invention relates to compounds which are polysufated oligosaccharide derivatives having activity as inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; methods for the preparation of the compounds; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and / or antithrombotic treatment, lowering of blood triglyceride levels and inhibition of cardiovascular disease of a mammalian subject.

The invention relates to a highly biologically active extracellular matrix material and its preparation method and application. The raw material is prepared by combined use of ultra-high pressure and perfusion inside and outside the cavity. The preparation method mainly includes: acquisition and preparation of raw materials, pre-treatment; mechanical separation of extracellular matrix; ultra-high pressure crushing and decellularization; washing out cell contents and removing antigens; final sterilization and preservation. Compared with the extracellular matrix obtained by decellularization by mechanical oscillation method, chemical reagent or biological reagent method, the present invention significantly improves the concentration of cohesin, growth factor, proteoglycan, glycoprotein, glycosaminoglycan, etc. The retention of biologically active components; at the same time, the mechanical strength is well preserved, the decellularization is thorough, and the biological load such as viruses is completely removed; the industrial production is convenient.

The present invention provides novel compounds and pharmaceutical compositions containing such compounds, wherein the compounds have affinity for proteoglycans. The compounds comprise an amino acid based core unit linked to positively charged moieties. The compounds further comprise at least one imaging moiety detectable in in vivo imaging making the compounds useful as diagnostic contrast agents for imaging of proteoglycans, such as heparan sulphate proteoglycans.

The present invention provides a kind of proteoglycan FMP-6-S4 containing galacturonan obtained from mulberry fruit (Fructus Mori), its preparation method, and described proteoglycan FMP-6-S4 in the preparation prevention and / or treatment of neurodegenerative diseases, inhibition of Aβ 42 Generation or aggregation or use in drugs or health products for Alzheimer's disease. The proteoglycan FMP‑6‑S4 comprises 78% to 82% by weight polysaccharide and 18% to 22% by weight protein; the polysaccharide is composed of galacturonic acid, galacturonic acid Lactose, arabinose, rhamnose and glucose. The proteoglycan FMP-6-S4 has a potential therapeutic effect on Alzheimer's disease, and is expected to be developed as a drug for treating Alzheimer's disease.

The present invention discloses acid and conjugated enzyme process for preparing fucan in lower molecular weight. Coarse fucan is enzymolyzed with commercial pectinase under controlled enzymolysis time, temperature and pH value and intercepted with ultrafiltering film of molecular weight 1000-5000 Da to obtain low molecular weight fucan. The present invention has simple operation, mild condition, high yield, low sulfate radical dropping rate, low cost and other advantages, and is easy use in industrial production. The present invention has simultaneous fucan extraction and lower molecular weight fucan preparation, and has simplified technological process, high production efficiency and over 30 % lowered production cost. In addition, the process uses no harmful chemical reagent, and the product is safe, non-toxic and especially suitable for producing functional food and medicine.